IRB #

STUDY00017155

Title

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is the test the safety of a study drug called DCC-2618 in participants with KIT or PDGFRA mutant GIST who have failed prior treatments. The study drug has been tested in animals, but not people.

Medical Condition(s)

KIT or PDGFRA mutant GIST

Eligibility Criteria

Age >18 with confirmed GIST that has failed prior treatments. Tests, procedures and a complete review of medical history will be done to confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

For up to two years if there is continued benefit or until a commercial supply is available. A 30 day safety period is also included once the study drug period ends.

Minors Included

No

Contact

Knight Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Deciphera Pharmaceuticals, LLC

Recruitment End

05/01/2018

Compensation Provided

No


Go Back